Navoximod

Navoximod

• CAS Number: 1402837-78-8
• UNSPSC Description: Navoximod (GDC-0919; NLG-?919) is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM.
• Target Antigen: Indoleamine 2,3-Dioxygenase (IDO)
• Type: Reference compound
• Related Pathways: Metabolic Enzyme/Protease
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/Navoximod.html
• Purity: 99.99
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: O[C@H](CC1)CC[C@]1([H])[C@H](O)C[C@@H]2N3C(C4=C2C(F)=CC=C4)=CN=C3
• Molecular Weight: 316.37
• References & Citations: [1]Mario R. Mautino, et al. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. AACR 104th Annual Meeting 2013; Apr 6-10, 2013.|[2]Li M, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21.|[3]Chen Y, et al. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun. 2016 Nov 7;7:13443.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C (Powder, stored under nitrogen)
• Clinical Information: Phase 1